Posts
- Category: News
- Inotek Pharmaceuticals Presents Preclinical Data in Support of Novel Glaucoma Candidate, INO-8875 at ARVO
- Inotek Pharmaceuticals Raises $21 Million to Support Ongoing Clinical Development of Trabodenoson, a Novel Eye Drop for the Treatment of Glaucoma
- Inotek Pharmaceuticals' Novel Glaucoma Candidate, INO-8875, Selected for Presentation at the ARVO 2009 Annual Meeting
- Inotek Pharmaceuticals' Novel Glaucoma Candidate, INO-8875, Significantly Reduces Intraocular Pressure in Phase 1/2 Study
- Category: Uncategorized
Pages
- 1996 Publications
- 1997 Publications
- Adenosine
- Age-Related Macular Degeneration
- Bimatoprost 0.03% (Bimatoprost)
- Careers & Benefits
- Careprost (Bimatoprost)
- Contact Information
- Diabetic Retinopathy and Macular Edema
- Generic Xalatan 0.005% (Latanoprost)
- Glaucoma
- INO-8875
- Inosine
- Inotek Pharmaceuticals
- Investors
- Lumigan (Bimatoprost)
- News
- Overview
- PARP
- PARP Inhibitors
- PARP inhibitors
- Partnering
- Pipeline Overview
- Research Products
- Retinal Diseases
- Scientific Approach
- Sitemap